Press release
Advanced Renal Cell Carcinoma Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang
"Advanced Renal Cell Carcinoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Renal Cell Carcinoma Market.
The Advanced Renal Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Advanced Renal Cell Carcinoma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Advanced Renal Cell Carcinoma treatment therapies with a considerable amount of success over the years.
*
Advanced Renal Cell Carcinoma companies working in the treatment market are Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others, are developing therapies for the Advanced Renal Cell Carcinoma treatment
*
Emerging Advanced Renal Cell Carcinoma therapies in the different phases of clinical trials are- OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others are expected to have a significant impact on the Advanced Renal Cell Carcinoma market in the coming years.
*
In March 2025, China-based Innovent Biologics and HUTCHMED are seeking approval for their cancer drug combination following a joint Phase II/III trial in kidney cancer that successfully achieved its primary and key secondary endpoints. The FRUSICA-2 study (NCT05522231) assessed the use of Innovent's Tyvyt (sintilimab) combined with HUTCHMED's Elunate (fruquintinib) as a second-line therapy for patients with locally advanced or metastatic renal cell carcinoma in China.
*
In December 2024, At the 2024 Society of Urologic Oncology (SUO) annual meeting in Dallas, Belzutifan was highlighted for its approval in multiple countries, including the United States and Canada, for treating patients with VHL disease-associated neoplasms. In the U.S., it is also approved for adult patients with advanced renal cell carcinoma (RCC) who have previously undergone treatment with a PD-(L)1 inhibitor and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI). Several studies have investigated the use of Belzutifan in advanced RCC patients. Dr. Jonasch presented the findings of a post hoc pooled analysis of Belzutifan's safety in RCC patients who received a 120 mg daily dose across the LITESPARK-001, LITESPARK-004, LITESPARK-005, and LITESPARK-013 studies.
*
In November 2024, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology firm focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, has announced the initiation of patient enrollment for its Phase 1 clinical trial assessing ADI-270 in individuals with metastatic or advanced clear cell renal cell carcinoma (ccRCC).
*
In September 2024, NiKang Therapeutics Registered Inc., a clinical-stage biotech company dedicated to developing innovative small molecule oncology treatments, announced that preliminary results from its ongoing Phase 1/2 clinical trial of NKT2152 for advanced clear cell renal cell carcinoma (ccRCC) in patients who have previously received treatment will be shared through an oral presentation at the European Society for Medical Oncology (ESMO) 2024 Congress.
Advanced Renal Cell Carcinoma Overview
Advanced Renal Cell Carcinoma (RCC) refers to a stage of kidney cancer where the cancer has spread beyond the kidney to other parts of the body. Renal cell carcinoma originates in the lining of small tubes in the kidney and can progress to an advanced stage if it metastasizes or spreads to nearby lymph nodes or distant organs.
Get a Free Sample PDF Report to know more about Advanced Renal Cell Carcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight [https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Advanced Renal Cell Carcinoma Drugs Under Different Phases of Clinical Development Include:
*
OATD-02: Molecure S.A.
*
DS-6000a: Daiichi Sankyo
*
JANX008: Janux Therapeutics
*
NKT2152: NiKang Therapeutics
*
CMN-001: CoImmune
*
IPI-549: Infinity Pharmaceuticals
*
TQB2450: Chia Tai TianqingPharmaceutical
*
Belzutifan: Merck Sharp & Dohme
*
Atezolizumab: Hoffmann-La Roche
*
Volrustomig: AstraZeneca
*
XmAb819: Xencor
Advanced Renal Cell Carcinoma Route of Administration
Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Advanced Renal Cell Carcinoma Molecule Type
Advanced Renal Cell Carcinoma Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment
*
Advanced Renal Cell Carcinoma Assessment by Product Type
*
Advanced Renal Cell Carcinoma By Stage and Product Type
*
Advanced Renal Cell Carcinoma Assessment by Route of Administration
*
Advanced Renal Cell Carcinoma By Stage and Route of Administration
*
Advanced Renal Cell Carcinoma Assessment by Molecule Type
*
Advanced Renal Cell Carcinoma by Stage and Molecule Type
DelveInsight's Advanced Renal Cell Carcinoma Report covers around 60+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Advanced Renal Cell Carcinoma product details are provided in the report. Download the Advanced Renal Cell Carcinoma pipeline report to learn more about the emerging Advanced Renal Cell Carcinoma therapies [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Advanced Renal Cell Carcinoma Therapeutics Market include:
Key companies developing therapies for Advanced Renal Cell Carcinoma are - Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, Teon Therapeutics, Asher Biotherapeutics, Shanghai Junshi Biosciences, Surface Oncology, ProfoundBio, Portage Biotech, Novartis Pharmaceuticals, HiFiBiO, and others.
Advanced Renal Cell Carcinoma Pipeline Analysis:
The Advanced Renal Cell Carcinoma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Renal Cell Carcinoma Treatment.
*
Advanced Renal Cell Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Advanced Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Renal Cell Carcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Advanced Renal Cell Carcinoma drugs and therapies [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Advanced Renal Cell Carcinoma Pipeline Market Drivers
*
Increasing Prevalence in Advanced Renal Cell Carcinoma, increase in the number of research and development activities are some of the important factors that are fueling the Advanced Renal Cell Carcinoma Market.
Advanced Renal Cell Carcinoma Pipeline Market Barriers
*
However, side-effects associated with the treatment of Advanced Renal Cell Carcinoma, cost associated with the treatment and other factors are creating obstacles in the Advanced Renal Cell Carcinoma Market growth.
Scope of Advanced Renal Cell Carcinoma Pipeline Drug Insight
*
Coverage: Global
*
Key Advanced Renal Cell Carcinoma Companies: Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang Therapeutics, CoImmune, Infinity Pharmaceuticals, Chia Tai TianqingPharmaceutical, Merck Sharp & Dohme, Hoffmann-La Roche, AstraZeneca, Xencor, and others
*
Key Advanced Renal Cell Carcinoma Therapies: OATD-02, DS-6000a, JANX008, NKT2152, CMN-001, IPI-549, TQB2450, Belzutifa, Atezolizumab, Volrustomig, XmAb819, and others
*
Advanced Renal Cell Carcinoma Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and Advanced Renal Cell Carcinoma emerging therapies
*
Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and Advanced Renal Cell Carcinoma market barriers
Request for Sample PDF Report for Advanced Renal Cell Carcinoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Advanced Renal Cell Carcinoma Report Introduction
2. Advanced Renal Cell Carcinoma Executive Summary
3. Advanced Renal Cell Carcinoma Overview
4. Advanced Renal Cell Carcinoma- Analytical Perspective In-depth Commercial Assessment
5. Advanced Renal Cell Carcinoma Pipeline Therapeutics
6. Advanced Renal Cell Carcinoma Late Stage Products (Phase II/III)
7. Advanced Renal Cell Carcinoma Mid Stage Products (Phase II)
8. Advanced Renal Cell Carcinoma Early Stage Products (Phase I)
9. Advanced Renal Cell Carcinoma Preclinical Stage Products
10. Advanced Renal Cell Carcinoma Therapeutics Assessment
11. Advanced Renal Cell Carcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Advanced Renal Cell Carcinoma Key Companies
14. Advanced Renal Cell Carcinoma Key Products
15. Advanced Renal Cell Carcinoma Unmet Needs
16 . Advanced Renal Cell Carcinoma Market Drivers and Barriers
17. Advanced Renal Cell Carcinoma Future Perspectives and Conclusion
18. Advanced Renal Cell Carcinoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-renal-cell-carcinoma-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-molecure-sa-daiichi-sankyo-janux-therapeutics-nikang]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Renal Cell Carcinoma Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics, NiKang here
News-ID: 4045097 • Views: …
More Releases from ABNewswire
Red Oak Hospice Brings Compassionate Care to Bridgeton: Tailored Palliative and …
Red Oak Hospice brings tailored palliative and hospice care to Bridgeton, ensuring local families receive compassionate support when they need it most.
Bridgeton, NJ - Red Oak Hospice, a trusted provider of compassionate end-of-life care, is proud to offer its expert hospice care services to families in the Bridgeton, NJ area. With a focus on personalized care, Red Oak Hospice ensures that individuals facing life-limiting illnesses and their families receive the…
MyIPNow Launches as a Next-Generation Suite of Free IP & Networking Tools for Gl …
So, there's this new thing called MyIPNow that just launched. It's basically a bunch of free tools for checking your IP address and other network stuff. It seems like they're trying to make it easier for everyone, no matter where they are, to get a handle on their internet connection and security. I've been hearing a bit about it, and it sounds like it could be pretty handy.
Key Takeaways
* MyIPNow…
Pixazo Launches Unified Visual AI API to Power the Next Generation of Multimodal …
Pixazo launches a Unified Visual AI API offering one-key access to 600+ models for image, video, audio, avatar, lip sync, and virtual try-on generation.
New Delhi, India - November 18, 2025 - Pixazo [https://www.pixazo.ai/] today announced the launch of its Unified Visual AI API, a single-key platform engineered to power the next great leap in digital creativity. As the world moves beyond text-based intelligence and into a multimodal era, Pixazo aims…
A Little Laughter, A Lot of Heart: Hannah's Docs & Ducks Reminds Families Why Re …
There's something special about a book that makes both kids and adults laugh at the same time. Docs & Ducks: A Quakery of Poems by Hannah is exactly that kind of book. It's light, funny, and a little bit thoughtful in ways you don't expect until you've turned the page.
The poems are short and easy to read, the kind you can slip into a bedtime routine or a classroom break.…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
